CoChat

Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis

Open access

The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.

Abstract

Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed. We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant–trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein–protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications. At Bonferroni significance (P < 5.63 × 10−5), Mendelian randomization analysis revealed six protein–multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79–0.89), 0.59 (95% CI, 0.48–0.71) and 0.88 (95% CI, 0.83–0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42–7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29–0.60) and CD5L (OR, 0.30; 95%CI, 0.18–0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awad070

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design for identification of plasma and CSF proteins causally associated with MS.
Figure 1 Study design for identification of plasma and CSF proteins causally associated with MS.CC BY-NC · PubMed Central
Figure 2 MR results for plasma and CSF proteins and the risk of MS. Volcano plots of the MR results for (A) 734 plasma and (B) 154 CSF proteins on the risk of MS. A and B show MR analysis with Wald ratio or inverse variance weighted method on plasma and CSF proteins on the risk of MS, respectively. OR for increased risk of MS were expressed as per SD increase in plasma protein levels and per 10-fold increase in CSF protein levels. Dashed horizontal black line corresponded to P = 5.63 × 10−5 (0.05/888). ln = natural logarithm; PVE = proportion of variance explained.
Figure 2 MR results for plasma and CSF proteins and the risk of MS. Volcano plots of the MR results for (A) 734 plasma and (B) 154 CSF proteins on the risk of MS. A and B show MR analysis with Wald ratio or inverse variance weighted method on plasma and CSF proteins on the risk of MS, respectively. OR for increased risk of MS were expressed as per SD increase in plasma protein levels and per 10-fold increase in CSF protein levels. Dashed horizontal black line corresponded to P = 5.63 × 10−5 (0.05/888). ln = natural logarithm; PVE = proportion of variance explained.CC BY-NC · PubMed Central
Figure 3 Interaction between current MS medications targets and identified potential drug targets.
Figure 3 Interaction between current MS medications targets and identified potential drug targets.CC BY-NC · PubMed Central
Figure 4 External validation of the causal relationship between six potential causal proteins and MS MR analysis on the causal relationship of six potential causal proteins on MS using data from (A) the UK Biobank and (B) the FinnGen cohort. OR for increased risk of MS were expressed as per SD increase in plasma protein levels and per 10-fold increase in CSF protein levels.
Figure 4 External validation of the causal relationship between six potential causal proteins and MS MR analysis on the causal relationship of six potential causal proteins on MS using data from (A) the UK Biobank and (B) the FinnGen cohort. OR for increased risk of MS were expressed as per SD increase in plasma protein levels and per 10-fold increase in CSF protein levels.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

Items 101–200 of 281

Metadata

Authors
Lin, J., Zhou, J., & Xu, Y.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Xu, Yan
Venue
Brain
Published
2023-03-02
Volume
146
Issue
8
Pages
3364-3372
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4323035146
Cited by
271
References
56
Citations by year
2026: 43 · 2025: 87 · 2024: 120 · 2023: 21
FWCI
55.94
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Peking Union Medical College Deposition Research Fund (ZC201904188)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Mapping and Diversity in Plants and Animals
Keywords
multiple sclerosis, therapeutic target, plasma proteins, cerebrospinal fluid protein, FCRL3, SLAMF7, CD5L, fetuin-A, thymidine phosphorylase, reverse causality, protein-protein interaction network, autoimmune disease, genetic risk factors, disease progression, relapse prevention, neuroinflammation, neurodegeneration
MeSH terms
Bayes Theorem, Humans, Multiple Sclerosis, Phenotype, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.